Benedikt W. Pelzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benedikt W. Pelzer has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Ari M. Melnick
Josep Carreras Leukaemia Research Institute, Barcelona, Spain
67 shared publications - Hans Christian Reinhardt
University Hospital Essen
67 shared publications - Gero Knittel
University Hospital Essen
42 shared publications - Wendy Béguelin
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
42 shared publications - Ruth Flümann
Department I of Internal Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hospital of Cologne University of Cologne Cologne Germany
41 shared publications - Christopher R. Chin
Department of Medicine, Weill Cornell Medicine, Cornell University, New York, USA
35 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutant lymphomas show signs of XChr dysregulation and TLR pathway dependencies.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutant lymphomas show signs of XChr dysregulation and TLR pathway dependencies.